Epoetin gamma
| Epoetin gamma | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Epoetin gamma is a recombinant DNA-derived form of erythropoietin, a glycoprotein hormone that regulates erythropoiesis (red blood cell production). It is used primarily in the treatment of anemia associated with chronic kidney disease and certain types of cancer.
Mechanism of Action[edit]
Epoetin gamma functions by stimulating the division and differentiation of committed erythroid progenitor cells in the bone marrow. It binds to the erythropoietin receptor on the surface of these progenitor cells, activating intracellular signaling pathways that lead to increased red blood cell production. This process is crucial for maintaining adequate oxygen transport in the body.
Clinical Uses[edit]
Epoetin gamma is indicated for the treatment of:
- Anemia due to chronic kidney disease in patients on dialysis and not on dialysis.
- Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy.
Administration and Dosage[edit]
Epoetin gamma is administered via subcutaneous or intravenous injection. The dosage and frequency depend on the patient's condition, hemoglobin levels, and response to treatment. Regular monitoring of hemoglobin levels is essential to adjust the dose and avoid complications such as hypertension and thrombosis.
Side Effects[edit]
Common side effects of epoetin gamma include:
- Hypertension
- Headache
- Joint pain
- Fever
- Nausea
Serious side effects may include:
- Increased risk of thromboembolic events
- Pure red cell aplasia (rare)
Pharmacokinetics[edit]
Epoetin gamma has a similar pharmacokinetic profile to endogenous erythropoietin. It is primarily metabolized in the liver and excreted by the kidneys. The half-life of epoetin gamma varies depending on the route of administration, with intravenous administration having a shorter half-life compared to subcutaneous administration.
Regulatory Status[edit]
Epoetin gamma is approved for use in several countries and is subject to regulation by agencies such as the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
Research and Development[edit]
Ongoing research is focused on optimizing the efficacy and safety of epoetin gamma, as well as exploring its use in other conditions associated with anemia.
Also see[edit]
Template:Erythropoiesis-stimulating agents Template:Anemia treatment
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
